Description: Symbiomix is a late-stage, privately held biopharmaceutical company with a focus on women’s health. The company’s lead product, SYM-1219, is a new anti-infective drug being studied as the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems

Location: Newark, NJ

Sector: Healthcare

Year Invested: 2013

Status: Acquired by Lupin Pharmaceuticals


Back to Companies

Associated Team Members